TB-500 Dosing Reference Guide: Species, Models & Published Ranges

Introduction

One of the most common barriers to initiating TB-500 research is the absence of a unified dosing reference. Published data are distributed across cardiac, musculoskeletal, wound healing, and neurological literature, often using inconsistent reporting conventions. This guide consolidates dosing parameters from peer-reviewed preclinical studies into a single searchable reference, organized by species and tissue system.

How to Use This Guide

1. Identify your species and injury model.
2. Find the corresponding row(s) in the reference tables.
3. Use the dose range as a starting point; consider your route and frequency based on protocol constraints.
4. Plan your reconstitution using the concentration matrix in the companion reconstitution guide.
5. Adjust for body weight: doses are given per kilogram; scale to your animal's actual weight at each dosing session.

Important Notes on Dose Scaling

• All doses expressed as µg/kg body weight unless noted.
• Body surface area (BSA) scaling is not standard for TB-500; most publications use linear weight-based dosing.
• Doses shown are total peptide per injection (not per day when frequency >1×/day).
• "i.p." = intraperitoneal; "s.c." = subcutaneous; "i.v." = intravenous; "i.l." = intralesional.

Mouse Dosing Reference

Muscle & Wound Models (Mouse)

| Injury Model | Dose Range | Route | Frequency | Duration | Reported Effect |

|-------------|-----------|-------|-----------|----------|----------------|

| Muscle crush (tibialis anterior) | 25–75 µg/kg | s.c. | 3×/week | 2–3 weeks | Faster satellite cell activation |

| Full-thickness wound | 50–100 µg/kg | s.c. | 3×/week | 2 weeks | 30–40% faster closure |

| Hindlimb ischemia | 50–150 µg/kg | i.p. | Daily | 2–4 weeks | Increased capillary density |

| Achilles transection | 50–100 µg/kg | s.c. | 3×/week | 2–4 weeks | Improved collagen alignment |

Cardiac Models (Mouse)

| Injury Model | Dose Range | Route | Frequency | Duration | Reported Effect |

|-------------|-----------|-------|-----------|----------|----------------|

| LAD ligation (permanent) | 25–150 µg/kg | i.p. | Daily | 4 weeks | 20–30% infarct reduction |

| Ischemia-reperfusion (30 min) | 50–150 µg/kg | i.p. | Daily | 2–4 weeks | Reduced cTnI, preserved EF |

| Doxorubicin cardiomyopathy | 50–100 µg/kg | s.c. | 3×/week | 4 weeks | Preserved cardiac function |

Neurological Models (Mouse)

| Injury Model | Dose Range | Route | Frequency | Duration | Reported Effect |

|-------------|-----------|-------|-----------|----------|----------------|

| Spinal cord contusion | 50–200 µg/kg | i.p. | Daily | 4–8 weeks | Modest motor recovery |

| Peripheral nerve crush | 50–100 µg/kg | s.c. | 3×/week | 4 weeks | Axon regeneration markers |

| TBI (controlled cortical impact) | 100–200 µg/kg | i.p. | Daily | 4 weeks | Reduced lesion volume |

Rat Dosing Reference

Muscle & Wound Models (Rat)

| Injury Model | Dose Range | Route | Frequency | Duration | Reported Effect |

|-------------|-----------|-------|-----------|----------|----------------|

| Muscle crush (gastrocnemius) | 50–150 µg/kg | s.c. | 3×/week | 3–4 weeks | Reduced fibrosis, faster twitch recovery |

| Full-thickness wound | 50–200 µg/kg | s.c. | Daily–3×/week | 2–3 weeks | Faster epithelialization, granulation |

| Burns (partial thickness) | 100–200 µg/kg | i.p. | Daily | 2 weeks | Reduced inflammation, faster re-epithelialization |

Tendon & Ligament Models (Rat)

| Injury Model | Dose Range | Route | Frequency | Duration | Reported Effect |

|-------------|-----------|-------|-----------|----------|----------------|

| Achilles transection (free) | 100–200 µg/kg | s.c. | 3×/week | 4 weeks | Improved UTS and stiffness |

| Achilles transection (repaired) | 50–150 µg/kg | s.c. | 3×/week | 4–6 weeks | Better Bonar histology score |

| Patellar tendon partial tear | 100–150 µg/kg | i.p. | Daily | 3 weeks | Improved collagen type I/III ratio |

| MCL sprain model | 50–150 µg/kg | s.c. | 3×/week | 3 weeks | Faster histological recovery |

| Supraspinatus tear | 100–150 µg/kg | i.l. | Weekly | 6 weeks | Improved fiber alignment |

Cardiac Models (Rat)

| Injury Model | Dose Range | Route | Frequency | Duration | Reported Effect |

|-------------|-----------|-------|-----------|----------|----------------|

| LAD ligation (permanent) | 50–150 µg/kg | i.p. | Daily–3×/week | 4–8 weeks | 25–35% infarct size reduction |

| Ischemia-reperfusion | 50–150 µg/kg | i.p. | Daily | 4 weeks | Preserved ejection fraction |

| Heart failure (tachypacing) | 100–200 µg/kg | s.c. | 3×/week | 6 weeks | Reduced BNP, improved CO |

Inflammation Models (Rat)

| Injury Model | Dose Range | Route | Frequency | Duration | Reported Effect |

|-------------|-----------|-------|-----------|----------|----------------|

| Carrageenan paw edema | 50–200 µg/kg | i.p. | Single dose | 1 day | Reduced paw volume (acute) |

| Collagen-induced arthritis | 100–200 µg/kg | s.c. | 3×/week | 4 weeks | Lower synovial inflammation score |

| LPS-induced peritonitis | 100–200 µg/kg | i.p. | Pre- or post-LPS | 1–3 days | Reduced IL-6, TNF-α |

Route of Administration Notes

| Route | Advantages | Disadvantages | Typical Use |

|-------|-----------|--------------|-------------|

| s.c. | Easy, low stress, depot effect | Slower absorption | Multi-week in vivo studies |

| i.p. | Rapid absorption, high bioavailability | More invasive, not translational | Acute/subacute models |

| i.v. | Immediate systemic exposure | Technical difficulty, bolus kinetics | Pharmacokinetic studies |

| i.l. | High local concentration | Technically demanding | Tendon, joint models |

Dosing Frequency Considerations

• Daily: Maximizes cumulative exposure; appropriate for acute injury windows (days 0–14 post-injury).
• 3×/week: Standard for chronic models; balances compound usage and animal stress.
• 2×/week: Used in some cardiac studies; may be adequate for maintenance phases.
• Once weekly: Documented in some tendon protocols for intralesional injection.

Calculating Dose Volume

Formula: Volume (mL) = [Dose (µg/kg) × BW (kg)] / [Concentration (µg/mL)]

Example: 100 µg/kg dose, 300 g rat, 2 mg/mL stock:

• Volume = (100 µg/kg × 0.3 kg) / 2,000 µg/mL = 30 µg / 2,000 µg/mL = 0.015 mL (15 µL)

For laboratory research only. Not for human administration.